Key Points
-
Macrophages and dendritic cells (DCs) are essential for the pathogenesis of rheumatoid arthritis (RA)
-
Phagocytosis of dying cells is necessary for the resolution of inflammation, and defects in this process can lead to rheumatic disease
-
Macrophage-specific and DC-specific defects in mediators of the extrinsic apoptotic pathway induce altered responses in experimental arthritis, and overexpression and/or deletion of components of the intrinsic apoptotic pathway influence the development of experimental arthritis
-
Global deletion of necroptotic signalling mediators results in a more rapid resolution of experimental arthritis, whereas macrophage-specific deletion of inhibitors of apoptosis exacerbates experimental arthritis
-
Autophagy might have a cell-specific inhibitory and proinflammatory role in RA and experimental arthritis
-
Risk polymorphisms in mediators of the extrinsic apoptotic pathway and autophagy have been identified in patients with RA
Abstract
Rheumatoid arthritis affects nearly 1% of the world's population and is a debilitating autoimmune condition that can result in joint destruction. During the past decade, inflammatory functions have been described for signalling molecules classically involved in apoptotic and non-apoptotic death pathways, including, but not limited to, Toll-like receptor signalling, inflammasome activation, cytokine production, macrophage polarization and antigen citrullination. In light of these remarkable advances in the understanding of inflammatory mechanisms of the death machinery, this Review provides a snapshot of the available evidence implicating death pathways, especially within the phagocyte populations of the innate immune system, in the perpetuation of rheumatoid arthritis and other rheumatic diseases. Elevated levels of signalling mediators of both extrinsic and intrinsic apoptosis, as well as the autophagy, are observed in the joints of patients with rheumatoid arthritis. Furthermore, risk polymorphisms are present in signalling molecules of the extrinsic apoptotic and autophagy death pathways. Although research into the mechanisms underlying these pathways has made considerable progress, this Review highlights areas where further investigation is particularly needed. This exploration is critical, as new discoveries in this field could lead to the development of novel therapies for rheumatoid arthritis and other rheumatic diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Helmick, C. G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15–25 (2008).
Lundy, S. K., Sarkar, S., Tesmer, L. A. & Fox, D. A. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res. Ther. 9, 202 (2007).
Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656–661 (2010).
Farache, J., Zigmond, E., Shakhar, G. & Jung, S. Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. Immunol. Cell Biol. 91, 232–239 (2013).
Galli, S. J., Borregaard, N. & Wynn, T. A. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat. Immunol. 12, 1035–1044 (2011).
van den Berg, W. B. & van Lent, P. L. E. M. The role of macrophages in chronic arthritis. Immunbiol. 195, 614–623 (1996).
Ziegler-Heitbrock, L. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116, e74–80 (2010).
Mulherin, D., Fitzgerald, O. & Bresnihan, B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 39, 115–124 (1996).
Yanni, G., Whelan, A., Feighery, C. & Bresnihan, B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 53, 39–44 (1994).
Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907–916 (2001).
Huang, Q., Ma, Y., Adebayo, A. & Pope, R. M. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum. 56, 2192–2201 (2007).
Chamberlain, N. D. et al. Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFα in monocytes. Ann. Rheum. Dis. 72, 418–426 (2013).
Huang, Q. & Pope, R. M. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J. Leukocyte Biol. 88, 253–262 (2010).
Nuki, G., Bresnihan, B., Bear, M. B. & McCabe, D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 2838–2846 (2002).
Genovese, M. C. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46, 1443–1450 (2002).
De Rycke, L. et al. Differential expression and response to anti-TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol. 206, 17–27 (2005).
Bresnihan, B. et al. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J. Rheumatol. 34, 620–622 (2007).
Wijbrandts, C. A. et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum. 56, 3869–3871 (2007).
Arandjelovic, S. & Ravichandran, K. S. Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. 16, 907–917 (2015).
Gatza, E. et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112, 1515–1521 (2008).
Hashimoto, D., Miller, J. & Merad, M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 35, 323–335 (2011).
Roszer, T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015, 816460 (2015).
Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593–604 (2010).
Odegaard, J. I. & Chawla, A. Alternative macrophage activation and metabolism. Annu. Rev. Pathol. 6, 275–297 (2011).
Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
Murray, P. J. et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity 41, 14–20 (2014).
Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274–288 (2014).
van Furth, R. & Cohn, Z. A. The origin and kinetics of mononuclear phagocytes. J. Exp. Med. 128, 415–435 (1968).
Edwards, J. C. & Willoughby, D. A. Demonstration of bone marrow derived cells in synovial lining by means of giant intracellular granules as genetic markers. Ann. Rheum. Dis. 41, 177–182 (1982).
Edwards, J. C. The nature and origins of synovium: experimental approaches to the study of synoviocyte differentiation. J. Anat. 184, 493–501 (1994).
Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79–91 (2013).
Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90 (2012).
Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010).
Amit, I., Winter, D. R. & Jung, S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat. Immunol. 17, 18–25 (2015).
Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547–551 (2015).
Gomez Perdiguero, E. et al. The origin of tissue-resident macrophages: when an erythro-myeloid progenitor is an erythro-myeloid progenitor. Immunity 43, 1023–1024 (2015).
Hoeffel, G. & Ginhoux, F. Ontogeny of tissue-resident macrophages. Front. Immunol. 6, 486 (2015).
Hoeffel, G. et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 42, 665–678 (2015).
Perdiguero, E. G. & Geissmann, F. The development and maintenance of resident macrophages. Nat. Immunol. 17, 2–8 (2015).
Varol, C., Mildner, A. & Jung, S. Macrophages: development and tissue specialization. Annu. Rev. Immunol. 33, 643–675 (2015).
Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792–804 (2013).
Jenkins, S. J. et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332, 1284–1288 (2011).
Davies, L. C. et al. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. Eur. J. Immunol. 41, 2155–2164 (2011).
Davies, L. C. et al. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nat. Commun. 4, 1886 (2013).
Misharin, A. V. et al. Nonclassical Ly6C- monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 9, 591–604 (2014).
Korns, D., Frasch, S. C., Fernandez-Boyanapalli, R., Henson, P. M. & Bratton, D. L. Modulation of macrophage efferocytosis in inflammation. Front. Immunol. 2, 57 (2011).
Lebre, M. C. et al. Rheumatoid arthritis synovium contains two subsets of CD83−DC-LAMP− dendritic Cells with Distinct Cytokine Profiles. Am. J. Pathol. 172, 940–950 (2008).
Thomas, R. & Quinn, C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J. Immunol. 156, 3074–3086 (1996).
Summers, K. L., O'Donnell, J. L., Williams, L. A. & Hart, D. N. Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis. Arthritis Rheum. 39, 1287–1291 (1996).
Page, G., Lebecque, S. & Miossec, P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J. Immunol. 168, 5333–5341 (2002).
Radstake, T. R. et al. Increased FcγRII expression and aberrant tumour necrosis factor α production by mature dendritic cells from patients with active rheumatoid arthritis. Ann. Rheum. Dis. 63, 1556–1563 (2004).
Radstake, T. R. et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum. 50, 3856–3865 (2004).
Ronnblom, L. & Alm, G. V. The natural interferon-α producing cells in systemic lupus erythematosus. Hum. Immunol. 63, 1181–1193 (2002).
van der Pouw Kraan, T. C. et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 66, 1008–1014 (2007).
Richez, C. et al. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res. Ther. 11, R100 (2009).
Thomas, R., Davis, L. S. & Lipsky, P. E. Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J. Immunol. 152, 2613–2623 (1994).
Pettit, A. R., MacDonald, K. P., O'Sullivan, B. & Thomas, R. Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum. 43, 791–800 (2000).
Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D. & Wigzell, H. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 79, 3632–3636 (1982).
Jongbloed, S. L. et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res. Ther. 8, R15 (2006).
Remijsen, Q. et al. Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ. 18, 581–588 (2011).
Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511–517 (2014).
Pope, R. M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2, 527–535 (2002).
Korb, A., Pavenstadt, H. & Pap, T. Cell death in rheumatoid arthritis. Apoptosis 14, 447–454 (2009).
Peter, M. E. et al. The CD95 receptor: apoptosis revisited. Cell 129, 447–450 (2007).
Green, D. R. Apoptotic pathways: the roads to ruin. Cell 94, 695–698 (1998).
Boatright, K. M., Deis, C., Denault, J. B., Sutherlin, D. P. & Salvesen, G. S. Activation of caspases-8 and -10 by FLIP(L). Biochem. J. 382, 651–657 (2004).
Micheau, O. et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277, 45162–45171 (2002).
Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl-2 interacting protein mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481–490 (1998).
Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479–489 (1997).
Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L. & Korsmeyer, S. J. BID, a novel BH3 domain only death agonist. Genes Dev. 10, 2859–2869 (1996).
Firestein, G. S. Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 96, 1631–1638 (1995).
Nakajima, T. et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum. 38, 485–491 (1995).
Hashmioto, H. et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 41, 657–662 (1998).
Pundt, N. et al. Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res. Ther. 11, R16 (2009).
Cantwell, M. J., Hua, T., Zvaifler, N. J. & Kipps, T. J. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 40, 1644–1652 (1997).
Wakisaka, S. et al. Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis. Clin. Exp. Immunol. 114, 119–128 (1998).
Kobayashi, T. et al. Differential regulation of Fas-mediated apoptosis of rheumatoid synoviocytes by tumor necrosis factor alpha and basic fibroblast growth factor is associated with the expression of apoptosis-related molecules. Arthritis Rheum. 43, 1106–1114 (2000).
Salmon, M. et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99, 439–446 (1997).
Migita, K. et al. Nitric oxide protects cultured rheumatoid synovial cells from Fas-induced apoptosis by inhibiting caspase-3. Immunology 103, 362–367 (2001).
Cohen, P. L. & Eisenberg, R. A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9, 243–269 (1991).
Ito, M. R. et al. Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum. 40, 1054–1063 (1997).
Cuda, C. M. et al. Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice. Arthritis Rheum. 64, 808–820 (2012).
Richez, C., Blanco, P., Rifkin, I., Moreau, J. F. & Schaeverbeke, T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 78, 124–130 (2010).
Brown, N. J. et al. Fas death receptor signaling represses monocyte numbers and macrophage activation in vivo. J. Immunol. 173, 7584–7593 (2004).
Ma, Y. et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat. Immunol. 380–387 (2004).
Huang, Q. Q. et al. Fas signaling in macrophages promotes chronicity in K/BxN serum-induced arthritis. Arthritis Rheumatol. 66, 68–77 (2014).
Stranges, P. B. et al. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 26, 629–641 (2007).
Kobayashi, T. et al. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes. Gene Ther. 7, 527–533 (2000).
Tourneur, L., Mistou, S., Schmitt, A. & Chiocchia, G. Adenosine receptors control a new pathway of Fas-associated death domain protein expression regulation by secretion. J. Biol. Chem. 283, 17929–17938 (2008).
Berckmans, R. J. et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res. Ther. 7, R536–544 (2005).
Vilmont, V., Tourneur, L. & Chiocchia, G. Fas-associated death domain protein and adenosine partnership: fad in RA. Rheumatology (Oxford) 51, 964–975 (2012).
Schock, S. N., Young, J. A., He, T. H., Sun, Y. & Winoto, A. Deletion of FADD in macrophages and granulocytes results in RIP3- and MyD88-dependent systemic inflammation. PLoS ONE 10, e0124391 (2015).
Young, J. A., He, T. H., Reizis, B. & Winoto, A. Commensal microbiota are required for systemic inflammation triggered by necrotic dendritic cells. Cell Rep. 3, 1932–1944 (2013).
Perlman, H. et al. Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum. 44, 21–30 (2001).
Catrina, A. I., Ulfgren, A. K., Lindblad, S., Grondal, L. & Klareskog, L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann. Rheum. Dis. 61, 934–936 (2002).
Schedel, J. et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum. 46, 1512–1518 (2002).
Perlman, H. et al. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J. Exp. Med. 190, 1679–1688 (1999).
Huang, Q. Q. et al. FLIP: a novel regulator of macrophage differentiation and granulocyte homeostasis. Blood 116, 4968–4977 (2010).
Gordy, C., Pua, H., Sempowski, G. D. & He, Y. W. Regulation of steady-state neutrophil homeostasis by macrophages. Blood 117, 618–629 (2011).
Huang, Q. Q. et al. CD11c-mediated deletion of Flip promotes autoreactivity and inflammatory arthritis. Nat. Commun. 6, 7086 (2015).
Wu, Y. J. et al. Cellular FLIP inhibits myeloid cell activation by suppressing selective innate signaling. J. Immunol. 195, 2612–2623 (2015).
Kamada, N. & Nunez, G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 146, 1477–1488 (2014).
Kabat, A. M., Srinivasan, N. & Maloy, K. J. Modulation of immune development and function by intestinal microbiota. Trends Immunol. 35, 507–517 (2014).
Lukens, J. R. et al. Dietary modulation of the microbiome affects autoinflammatory disease. Nature 516, 246–249 (2014).
Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).
Helfer, B. et al. Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res. 66, 4273–4278 (2006).
Dohrman, A. et al. Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF-kappa B activation. J. Immunol. 174, 5270–5278 (2005).
Rajput, A. et al. RIG-I RNA helicase activation of IRF3 transcription factor is negatively regulated by caspase-8-mediated cleavage of the RIP1 protein. Immunity 34, 340–351 (2011).
Kovalenko, A. et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J. Exp. Med. 206, 2161–2177 (2009).
Hu, W. H., Johnson, H. & Shu, H. B. Activation of NF-kappaB by FADD, Casper, and caspase-8. J. Biol. Chem. 275, 10838–10844 (2000).
Sears, N., Sen, G. C., Stark, G. R. & Chattopadhyay, S. Caspase-8-mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation. J. Biol. Chem. 286, 33037–33044 (2011).
Cuda, C. M. et al. Conditional deletion of caspase-8 in macrophages alters macrophage activation in a RIPK-dependent manner. Arthritis Res. Ther. 17, 291 (2015).
Kang, T. B. et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173, 2976–2984 (2004).
Cuda, C. M. et al. Caspase-8 acts as a molecular rheostat to limit RIPK1- and MyD88-mediated dendritic cell activation. J. Immunol. 192, 5548–5560 (2014).
Kang, T. B., Yang, S. H., Toth, B., Kovalenko, A. & Wallach, D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38, 27–40 (2013).
Adams, J. M. & Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322–1326 (1998).
Delbridge, A. R. & Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 22, 1071–1080 (2015).
Opferman, J. T. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J. http://dx.doi.org/10.1111/febs.13472 (2015).
Perlman, H. et al. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J. Immunol. 164, 5227–5235 (2000).
Busteed, S. et al. Bcl-x(L) expression in vivo in rheumatoid synovium. Clin. Rheumatol 25 789–793 (2006).
Liu, H. et al. Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 54, 3174–3181 (2006).
Liu, H. et al. Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J. Immunol. 175, 8337–8345 (2005).
Cha, H. S., Rosengren, S., Boyle, D. L. & Firestein, G. S. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum. 54, 587–592 (2006).
Hilbers, I. et al. Expression of the apoptosis accelerator Bax in rheumatoid arthritis synovium. Rheumatol Int. 23, 75–81 (2003).
Scatizzi, J. C. et al. Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum. 62, 441–451 (2010).
Zheng, B. et al. Overexpression of Bcl(XL) in B cells promotes TH1 response and exacerbates collagen-induced arthritis. J. Immunol. 179, 7087–7092 (2007).
Chen, Y., Rosloniec, E., Price, J., Boothby, M. & Chen, J. Constitutive expression of BCL-X(L) in the T lineage attenuates collagen-induced arthritis in Bcl-X(L) transgenic mice. Arthritis Rheum. 46, 514–521 (2002).
Lawlor, K. E. et al. Bcl-2 overexpression ameliorates immune complex-mediated arthritis by altering FcγRIIb expression and monocyte homeostasis. J. Leukocyte Biol. 93, 585–597 (2013).
Bardwell, P. D. et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J. Immunol. 182, 7482–7489 (2009).
Lawlor, K. E., Smith, S. D., van Nieuwenhuijze, A., Huang, D. C. & Wicks, I. P. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis. J. Leukocyte Biol. 90, 819–829 (2011).
Scatizzi, J. C. et al. Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis. Arthritis Rheum. 54, 3182–3193 (2006).
Scatizzi, J. C. et al. Pro-apoptotic Bid is required for the resolution of the effector phase of inflammatory arthritis. Arthritis Res. Ther. 9, R49 (2007).
Bouillet, P. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735–1738 (1999).
Hutcheson, J. et al. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity 28, 206–217 (2008).
Hutcheson, J. & Perlman, H. BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention. Oncogene 27 (Suppl. 1), S168–S175 (2008).
Egle, A., Harris, A. W., Bath, M. L., O'Reilly, L. & Cory, S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276–2283 (2003).pii] (2004).
Zhou, P. et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 97, 3902–3909 (2001).
Zhou, P. et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92, 3226–3239 (1998).
Chen, M., Huang, L. & Wang, J. Deficiency of Bim in dendritic cells contributes to over-activation of lymphocytes and autoimmunity. Blood 109, 4360–4367 (2007).
Gautier, E. L. et al. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock. J. Immunol. 180, 6941–6946 (2008).
Nopora, A. & Brocker, T. Bcl-2 controls dendritic cell longevity in vivo. J. Immunol. 169, 3006–3014 (2002).
Hou, W. S. & Van Parijs, L. A. Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5, 583–589 (2004).
Yeretssian, G. et al. Non-apoptotic role of BID in inflammation and innate immunity. Nature 474, 96–99 (2011).
Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311–320 (2015).
Oberst, A. et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471, 363–367 (2011).
Feoktistova, M. et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43, 449–463 (2011).
Vince, J. E. et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 36, 215–227 (2012).
Gurung, P. et al. FADD and Caspase-8 Mediate Priming and Activation of the Canonical and Noncanonical Nlrp3 Inflammasomes. J. Immunol. 192, 1835–1846 (2014).
Shenderov, K. et al. Cutting edge: endoplasmic reticulum stress licenses macrophages to produce mature IL-1β in response to TLR4 stimulation through a caspase 8- and TRIF-dependent pathway. J. Immunol. 192, 2029–2033 (2014).
Zhang, H. et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471, 373–376 (2011).
Newton, K., Sun, X. & Dixit, V. M. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell. Biol. 24, 1464–1469 (2004).
Kaiser, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368–372 (2011).
Dillon, C. P. et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 1, 401–407 (2012).
Lawlor, K. E. et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat. Commun. 6, 6282 (2015).
Lattuada, D. et al. Proapoptotic activity of a monomeric smac mimetic on human fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflammation 38, 102–109 (2015).
Deveraux, Q. L. et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17, 2215–2223 (1998).
Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33–42 (2000).
Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43–53 (2000).
Shin, Y. J. et al. Autophagy induction and CHOP under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under endoplasmic reticulum stress. Arthritis Res. Ther. 12, R19 (2010).
Xu, K. et al. Reduced apoptosis correlates with enhanced autophagy in synovial tissues of rheumatoid arthritis. Inflamm Res. 62, 229–237 (2013).
Kato, M., Ospelt, C., Gay, R. E., Gay, S. & Klein, K. Dual role of autophagy in stress-induced cell death in rheumatoid arthritis synovial fibroblasts. Arthritis Rheumatol. 66, 40–48 (2014).
Buckland, J. Rheumatoid arthritis: Autophagy: a dual role in the life and death of RASFs. Nat. Rev. Rheumatol 9, 637 (2013).
Allan, L. A. & Clarke, P. R. Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation. FEBS J. 276, 6063–6073 (2009).
Cronstein, B. N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57, 163–172 (2005).
Nakazawa, F. et al. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J. Rheumatol 28, 1800–1808 (2001).
Smith, M. D. et al. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 49, 862–875 (2010).
Xu, K. et al. Autophagy induction contributes to the resistance to methotrexate treatment in rheumatoid arthritis fibroblast-like synovial cells through high mobility group box chromosomal protein 1. Arthritis Res. Ther. 17, 374 (2015).
Yang, Z., Fujii, H., Mohan, S. V., Goronzy, J. J. & Weyand, C. M. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J. Exp. Med. 210, 2119–2134 (2013).
Ireland, J. M. & Unanue, E. R. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J. Exp. Med. 208, 2625–2632 (2011).
Wegner, N. et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233, 34–54 (2010).
Lin, N. Y. et al. Autophagy regulates TNFalpha-mediated joint destruction in experimental arthritis. Ann. Rheum. Dis. 72, 761–768 (2013).
Onuora, S. Bone research: Autophagy is central to joint destruction in arthritis. Nat. Rev. Rheumatol 8, 633 (2012).
Yan, H., Zhou, H. F., Hu, Y. & Pham, C. T. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J. Rheum. Dis. Treat. 1, 5 (2015).
Orozco, G. et al. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 70, 463–468 (2011).
Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207–211 (2007).
Palomino-Morales, R. J. et al. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. Genes Immun. 10, 356–364 (2009).
Lubberts, E., Koenders, M. I. & van den Berg, W. B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7, 29–37 (2005).
Nakae, S., Nambu, A., Sudo, K. & Iwakura, Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171, 6173–6177 (2003).
Luross, J. A. & Williams, N. A. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 103, 407–416 (2001).
Wenink, M. H., Han, W., Toes, R. E. & Radstake, T. R. Dendritic cells and their potential implication in pathology and treatment of rheumatoid arthritis. Handb Exp. Pharmacol. 188, 81–98 (2009).
Kelchtermans, H. et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res. Ther. 11, R122 (2009).
Billiau, A. & Matthys, P. Collagen-induced arthritis and related animal models: how much of their pathogenesis is auto-immune, how much is auto-inflammatory? Cytokine Growth Factor Rev. 22, 339–344 (2011).
Genovese, M. C. et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. 72, 863–869 (2013).
Matsumoto, I., Staub, A., Benoist, C. & Mathis, D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286, 1732–1735 (1999).
Bevaart, L., Vervoordeldonk, M. J. & Tak, P. P. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum. 62, 2192–2205 (2010).
Ji, H. et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157–168 (2002).
Korganow, A. S. et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10, 451–461 (1999).
Maccioni, M. et al. Arthritogenic monoclonal antibodies from K/BxN mice. J. Exp. Med. 195, 1071–1077 (2002).
Corr, M. & Crain, B. The role of FcγR signaling in the K/B x N serum transfer model of arthritis. J. Immunol. 169, 6604–6609 (2002).
Ji, H. et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 196, 77–85 (2002).
Manganelli, P. & Fietta, P. Apoptosis and Sjogren syndrome. Semin. Arthritis Rheum. 33, 49–65 (2003)
Zhu, A. et al. Fas/FasL, Bcl2 and Caspase-8 gene polymorphisms in Chinese patients with rheumatoid arthritis. Rheumatol. Int. 36, 807–818 (2016).
Anaya, J. M., Mantilla, R. D. & Correa, P. A. Immunogenetics of primary Sjogren's syndrome in Colombians. Semin. Arthritis Rheum. 34, 735–743 (2005).
Delgado-Vega, A. M. et al. Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women. Ann. Rheum. Dis. 69, 462–465 (2010).
Kollek, M., Muller, A., Egle, A. & Erlacher, M. Bcl-2 proteins in development, health and disease of the hematopoietic system. FEBS J. http://dx.doi.org/10.1111/febs.13683 (2016).
Ogilvy, S. et al. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc. Natl Acad. Sci. USA 96, 14943–14948 (1999).
Fang, W. et al. Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a Bcl-xL transgene. Immunity 4, 291–299 (1996).
Chao, D. T. & Korsmeyer, S. J. BCL-XL-regulated apoptosis in T cell development. Int. Immunol. 9, 1375–1384 (1997).
Bonilla, D. L. et al. Autophagy regulates phagocytosis by modulating the expression of scavenger receptors. Immunity 39, 537–547 (2013).
Acknowledgements
This work was supported by grants from the NIH to C.M.C. (K01AR064313), R.M.P. (AR065076, AR067687) and H.P. (AR064546, AR050250, AR054796, AI092490, HL108795), and funds provided to R.M.P. from the Pfizer Aspire award and to H.P. by the Solovy-Arthritis Research Society Chair in Medicine.
Author information
Authors and Affiliations
Contributions
C.C. researched data for the article. All authors substantially contributed to discussion of content, and reviewed/edited the manuscript before submission. C.C. and H.P. wrote the article.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- Apoptosis
-
A process of programmed cell death
- Phagocytosis
-
A process by which a cell engulfs bacteria, parasites, dead host cells and cellular and foreign debris.
- Efferocytosis
-
A process similar to, yet distinct from, phagocytosis, whereby phagocytes engulf and eliminate apoptotic cells to promote the resolution of inflammation.
- Splenomegaly
-
Abnormal enlargement of the spleen.
- Lymphadenopathy
-
A disease characterized by abnormal size, number or consistency of lymph nodes.
- Hypergammaglobulinaemia
-
A condition characterized by increased levels of immunoglobulins in the blood serum.
- Glomerulonephritis
-
Acute inflammation of the kidney, typically caused by an immune response.
- Proteinuria
-
The presence of abnormal quantities of proteins in the urine, which might indicate damage to the kidneys.
- Necroptosis
-
A programmed form of necrosis or inflammatory cell death.
- Citrullination
-
The conversion of the amino acid arginine within a protein to the amino acid citrulline.
Rights and permissions
About this article
Cite this article
Cuda, C., Pope, R. & Perlman, H. The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases. Nat Rev Rheumatol 12, 543–558 (2016). https://doi.org/10.1038/nrrheum.2016.132
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.132
This article is cited by
-
YKL-40 in serum: a promising biomarker of juvenile SLE and strongly correlated with disease duration
Irish Journal of Medical Science (1971 -) (2023)
-
Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells
Nature Communications (2020)
-
TonEBP in dendritic cells mediates pro-inflammatory maturation and Th1/Th17 responses
Cell Death & Disease (2020)
-
iNOS dependent and independent phases of lymph node expansion in mice with TNF-induced inflammatory-erosive arthritis
Arthritis Research & Therapy (2019)
-
PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma
Oncogenesis (2019)